<DOC>
	<DOCNO>NCT00539968</DOCNO>
	<brief_summary>This study determine best dos docetaxel lonafarnib two anti-cancer agent use combination . Patients tumor treatment docetaxel would appropriate eligible . A second part study examine effectiveness combination treatment men prostate cancer .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Activity Lonafarnib Docetaxel ( Study P04467AM1 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>For Part 1 : Subjects may male female must least 18 year age . For Part 1 : Cancer docetaxel treatment appropriate . For Part 1 : Docetaxelna√Øve For Part 2 : Subjects must male least 18 year age . For Part 2 : Subjects must adenocarcinoma prostate confirm histologic/cytologic biopsy . For Part 2 : Subjects must progressive , metastatic , AIPC PSA 10 ng/ml hormonal therapy prior docetaxel treatment . Progressive disease define consistently increase serum PSA level within 28 day prior docetaxel administration . Adequate organ function within 3 week prior first study drug administration . Performance status ( ECOG ) less equal 2 . Subject understands agree procedure participation signing informed consent form . Agrees use medically accept form contraception . Receipt need continue receive prohibit medication ( list protocol ) recently washout period ( indicated protocol ) . Surgery within 3 week prior first study drug administration . History within 5 year prior first study drug administration another malignancy except adequately treat Stage I/II basal/squamous cell skin cancer . Radiation therapy 25 % his/her total bone marrow life . Radiation therapy within 3 week prior first study drug administration . Known hypersensitivity prednisone , docetaxel , polysorbate 80 , lonafarnib , excipients associate medication . Known contraindication steroid use . Known leptomeningeal CNS metastasis . Heart , vascular , seizure disorder ( detailed list protocol ) within 6 month prior first study drug administration . Baseline QTc interval great 450 msec . Grade 2 peripheral neuropathy drugrelated toxicity per CTCAE . Exceptions note protocol . Any clinically significant condition situation investigator think would interfere study evaluation subject 's participation . Subject part staff personnel involve study . Subject know clinically significant immunosuppression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>